Lannett And FDA To Meet Over Insulin Glargine Biosimilar

Follow-On To Lantus Being Developed With China’s HEC Pharm

 
• By Dean Rudge
Lantus
Lannett has ambitious goals to become a $1bn company, fuelled by launches like biosimilar Lantus • Source: Shutterstock

More from Biosimilars

More from Products